Kythera deal

[whateva]

http://www.nytimes.com/2015/06/18/bu...lion.html?_r=0

[It's2014ComeOnAlready]

Whaaaatt?? I guess they're trying to corner the hair loss market lol

[GSD]

good sign or not?

[It's2014ComeOnAlready]

good sign or not?

Great sign. It could mean that bimatoprost works, and they want to corner the hair loss market with a drug that will stop your hair loss (Setipiprant) and one that will regrow (bim).

Sure they'll want that injectable fat-burning drug, because they want to build on what they have in aesthetics, but it's likely that the pairing of seti and bim would absolutely corner the hair loss market.

[20legend]

Could be a good sign. But the don't mention anything about either of the drugs in the press release statements by Allergan.
Only stuff about their double chin products.

[dus]

This looks pretty good indeed. No guarantees though.

[It's2014ComeOnAlready]

From Brent Saunders, CEO of Allergan:

"The acquisition of KYTHERA is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth. Kybella is an exciting new product that offers patients the first and only clinically-proven, non-surgical treatment for submental fullness (excess fat under the chin). As a leader in aesthetics, we know our customers are looking to offer their patients new options beyond traditional facial aesthetics. Kybella will do that while complementing our market leading facial aesthetics portfolio, which includes Botox, Juvederm XC, Juvederm Voluma XC, Latisse and Skinmedica. Kybella is also a pivotal entry point for expanding the use of facial aesthetic products in men, while Kythera’s setipiprant (hair-loss) development program can drive additional long-term value."

Interesting that he puts enough stock in this drug, given that it is "hypothesis driven."

Also, the Wall Street Journal calls the acquisition "pricey," given that Kybella is expected to get peak sales of $500 million, annually. Look at how many injectable drugs they already have, but $2 billion?

[FearTheLoss]

This is a very very good sign! for me, because I bought Kythera at $30 a share, and for all of us because I think this could be a sign that bim works and they do want to corner the market with a pgd2 inhibitor. Exciting stuff! Hopefully, this doesn't delay the beginning of the setipiprant trials though

[FearTheLoss]

In my opinion, they would have never bought Kythera for 2.1 billion for just the chin treatment. Seti is literally the only other thing in the pipeline, they have to be trying to corner the hair loss market. There are just too many connections.

[It's2014ComeOnAlready]

In my opinion, they would have never bought Kythera for 2.1 billion for just the chin treatment. Seti is literally the only other thing in the pipeline, they have to be trying to corner the hair loss market. There are just too many connections.

Yep. The Wall Street Journal thought it was a lot too, just for the injectable. I completely agree.